lovastatin has been researched along with Diabetes Mellitus, Type 2 in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.25) | 18.7374 |
| 1990's | 26 (54.17) | 18.2507 |
| 2000's | 12 (25.00) | 29.6817 |
| 2010's | 6 (12.50) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Ding, L; Li, R; Lu, Q; Lu, S; Lyu, L; Ma, Z; Xu, H | 1 |
| Argani, H; Azizi, T; Gholamin, S; Ghorbanihaghjo, A; Rashtchizadeh, N; Razavi, SM; Safa, J; Taghavi-Garmestani, SM; Vatankhah, AM | 1 |
| Ahmadi, F; Mohebi-Nejad, A | 1 |
| Chen, D; Li, J; Ma, JX; Mott, R; Wang, JJ; Yu, Q; Zhang, SX | 1 |
| Argani, H; Ghorbanihaghjo, A; Montazer-Saheb, S; Nezami, N; Rashtchizadeh, N; Safa, J | 1 |
| Eftekhar-Sadat, AT; Ghorashi, S; Khosraviani, K; Nezami, N; Safa, J; Sakhaee, K; Salari, B | 1 |
| Kang, W; Kim, Y; Park, K | 1 |
| Davari-Farid, S; Ghorashi, S; Hashemi-Aghdam, Y; Khosraviani, K; Nargabad, ON; Nezami, N; Safa, J; Salari, B; Tabrizi, JS | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Alvarez, E; Amor, A; Castaño, G; Fernández, JL; González, RL; Lezcay, M; Más, R; Menéndez, R | 1 |
| Kamanna, VS; Kashyap, ML; Meyers, CD | 1 |
| Alende Sixto, MR; Martínez Rey, C; Rodríguez Framil, M; Torre Carballada, JA | 1 |
| Chan, YH; Lim, SC; Sum, CF; Tavintharan, S | 1 |
| Fineman, M; Han, J; Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, M; Pena, A; Reddy, S; Skrivanek, Z | 1 |
| Amini, M; Aminorroaya, A; Janghorbani, M; Safaei, H | 1 |
| Bozhko, GKh; Chursina, VS; Pertseva, TG; Sokolik, VV | 1 |
| Iwasaki, T; Kato, S; Sasaki, H; Tada, N | 1 |
| Cheng, IK; Janus, ED; Lam, KS; Pang, RW | 1 |
| Appel, S; Hitzenberger, G; Kalafsky, G; Kallay, Z; Kutz, K; Rüfenacht, T; Tetzloff, W | 1 |
| Amano, M; Ino, T; Kasuga, M; Kazumi, T; Matsuba, K; Ohki, A; Yoshino, G | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Daubresse, JC; Machowski, R; Pulinx, E | 1 |
| Alberti, KG; Evans, K; Farrer, M; Kesteven, P; Laker, MF; Neil, HA; Winocour, PH | 1 |
| Camarda, G | 1 |
| Foresta, C; Guarneri, G; Lavagnini, T; Padovan, D; Rossato, M | 1 |
| Alberti, KG; Klausen, IC; Mogensen, CE; Møller, N; Nielsen, S; Pørksen, N; Schmitz, O | 1 |
| Peres, RB; Plavinik, F; Ribeiro, AB; Zampieri, M; Zanella, MT | 1 |
| Alemanno, N; Cassader, M; Gambino, R; Pagano, G; Ruiu, G; Veglia, F | 1 |
| Parving, HH | 1 |
| Chang, CL; Ho, LT; Hwu, CM; Kwok, CF; Shih, KC | 1 |
| Miura, Y; Nakano, H; Nishimura, M; Sakai, O; Shibasaki, T; Suzuki, S; Tuchida, H; Wakabayashi, Y; Yamada, K | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Bressler, P; DeFronzo, RA; Kudolo, GB | 1 |
| Chan, DC; Chow, CC; Cockram, CS; Ko, GT; Lam, CW; Mak, TW; Tsang, LW; Yeung, VT | 1 |
| Gotto, AM | 1 |
| Castaño, G; Crespo, N; Fernández, J; Fernández, L; Illnait, J; Más, R | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Chen, X; Hu, P; Huang, D; Huang, M; Xie, M; Yu, Y; Zhang, H | 1 |
| Taskinen, MR | 1 |
| Bonnici, F; Fourie, J; Kotze, TJ; Lourens, W; Omar, MA; Stander, I; Steyn, K; van Lathem, J; Vermaak, WJ; Weich, HF | 1 |
| Beghè, F; Frustaci, G; Notarangelo, R; Pentimone, F; Pipicelli, G | 1 |
| D'Onofrio, F; De Riu, S; Gambardella, A; Paolisso, G; Sgambato, S; Varricchio, M; Verza, M | 1 |
| Goldberg, R; La Belle, P; Ronca, P; Zupkis, R | 1 |
| Allan, J; Johnson, BF; LaBelle, P; Ronca, PD; Wilson, J; Zupkis, RV | 1 |
| Garg, A; Grundy, SM | 3 |
2 review(s) available for lovastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Niacin therapy in atherosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Lovastatin; Niacin; Randomized Controlled Trials as Topic | 2004 |
Diabetic dyslipidemia.
Topics: Apolipoproteins; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lovastatin; Prevalence; Risk Factors | 2002 |
23 trial(s) available for lovastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Topics: Adult; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Leptin; Lovastatin; Male; Middle Aged | 2014 |
Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
Topics: Blood Glucose; Demography; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Osteoprotegerin | 2010 |
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyperlipidemias; Lipid Metabolism; Lipid Peroxidation; Lipids; Lovastatin; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2002 |
Exenatide effects on statin pharmacokinetics and lipid response.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Exenatide; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Lovastatin; Male; Middle Aged; Peptides; Venoms | 2007 |
Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Aged; Bone Density; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lumbar Vertebrae; Middle Aged; Postmenopause | 2007 |
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Apoprotein(a); Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, Diabetic; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Lovastatin; Male; Middle Aged; Placebos; Single-Blind Method; Time Factors; Triglycerides | 1995 |
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Glyburide; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Lovastatin; Placebos; Simvastatin; Tolbutamide | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
Topics: Adult; Aged; Apolipoproteins B; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemostasis; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Female; Fructosamine; Glomerular Filtration Rate; Glycated Hemoglobin; Hexosamines; Humans; Hypercholesterolemia; Insulin; Kidney; Lovastatin; Male; Placebos; Simvastatin; Time Factors | 1993 |
[Lovastatin in the treatment of hypercholesterolemia in non-insulin-dependent diabetes mellitus patients].
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged | 1993 |
Lovastatin lowers serum cholesterol levels in non-insulin-dependent diabetes mellitus patients without altering their insulin sensitivity.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Insulin; Insulin Resistance; Lovastatin; Male; Middle Aged | 1996 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines | 1998 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Topics: Anticholesteremic Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Alcohols; Female; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Treatment Outcome | 1999 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1989 |
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Topics: Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Random Allocation | 1988 |
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Triglycerides | 1988 |
23 other study(ies) available for lovastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Renal Resistive Index as a Novel Indicator for Renal Complications in High-Fat Diet-Fed Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Fibrosis; Glomerular Filtration Rate; Kidney; Lovastatin; Male; Mice; Mice, Inbred C57BL; Renal Artery; Ultrasonography | 2017 |
Re: Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Leptin; Lovastatin; Male | 2014 |
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
Topics: Animals; Blood-Retinal Barrier; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Evaluation, Preclinical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lovastatin; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Retina; Retinal Pigment Epithelium; Tight Junctions; Tumor Necrosis Factor-alpha | 2009 |
C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.
Topics: Adult; Aged; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Triglycerides | 2009 |
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P450 Family 2; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indoles; Lovastatin; Male; Nateglinide; Nifedipine; Phenylalanine; Rabbits; Steroid 21-Hydroxylase; Verapamil | 2010 |
Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Time Factors; Uric Acid; Withholding Treatment | 2012 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Hypothyroidism and lovastatin-induced myositis].
Topics: Aged; Diabetes Mellitus, Type 2; Disease Susceptibility; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Lovastatin; Myositis | 2005 |
Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Topics: Apolipoproteins E; Cholesterol; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Simvastatin; Treatment Outcome | 2007 |
[A short-term effect of lovastatin on lipoprotein metabolism in patients with cerebrovascular lesions concomitant with diabetes mellitus II type].
Topics: Biomarkers; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin; Male; Middle Aged; Time Factors; Treatment Outcome | 2006 |
High retinol/retinol-binding protein ratio in noninsulin-dependent diabetes mellitus.
Topics: Anticholesteremic Agents; Antioxidants; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; beta Carotene; Blood Glucose; Carotenoids; Cholesterol; Diabetes Mellitus, Type 2; Diterpenes; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Retinol-Binding Proteins; Retinyl Esters; Sex Characteristics; Simvastatin; Triglycerides; Vitamin A | 1995 |
Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors; Simvastatin | 1995 |
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
[Use and effect of simvastin in patients with type II diabetes].
Topics: Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Simvastatin influences testicular steroidogenesis in human.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypothalamo-Hypophyseal System; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Testicular Hormones; Testis; Triglycerides | 1993 |
Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lovastatin; Proteinuria; Research Design | 1996 |
[Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus].
Topics: Albuminuria; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Tissue Plasminogen Activator; von Willebrand Factor | 1996 |
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hyperinsulinism; Insulin; Lovastatin; Male; Middle Aged; Obesity; Phospholipases A | 1997 |
[Effects of lovastatin on plasma lipid, plasma glucose and insulin metabolism of patients with type II B hyperlipemia].
Topics: Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Lovastatin; Male; Middle Aged | 1999 |
[Diabetes mellitus, hypercholesterolemia, and therapeutic prospects with simvastatin. General considerations and personal contribution].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Effects of lovastatin in diabetic patients treated with chlorpropamide.
Topics: Acyl Coenzyme A; Administration, Oral; Apolipoproteins B; Blood Glucose; Chlorpropamide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Time Factors | 1990 |